158 related articles for article (PubMed ID: 37872693)
1. ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia.
Duran Luciano P; Sabella-Jiménez V
Tex Heart Inst J; 2023 Oct; 50(5):. PubMed ID: 37872693
[TBL] [Abstract][Full Text] [Related]
2. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
[TBL] [Abstract][Full Text] [Related]
3. Acute myocardial infarction revealing a polycythemia vera.
Gouri A; Yakhlef A; Dekaken A; Bentorki AA
Ann Biol Clin (Paris); 2012; 70(4):489-91. PubMed ID: 22796622
[TBL] [Abstract][Full Text] [Related]
4. Compound in-cis JAK2 mutant polycythemia vera manifesting as first-onset transient ischemic attack with erythrocytosis and an attenuated JAK2 V617F mutant signal on a quantitative DD-PCR assay.
Ng IKS; Lee PL; Ng LJ; Chua RP; Ng YA; Lee CK; Tan JG; Chan THM; Yan B; Prasad V
Int J Lab Hematol; 2023 Apr; 45(2):e28-e31. PubMed ID: 36205319
[No Abstract] [Full Text] [Related]
5. JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
Inami T; Okabe M; Matsushita M; Kobayashi N; Inokuchi K; Hata N; Seino Y; Shimizu W
Heart Vessels; 2016 Oct; 31(10):1714-6. PubMed ID: 26825737
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
[TBL] [Abstract][Full Text] [Related]
7. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
8. Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Wen H; Jin D; Chen Y; Cui B; Xiao T
BMC Neurol; 2021 Jun; 21(1):225. PubMed ID: 34134639
[TBL] [Abstract][Full Text] [Related]
9. Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.
Benmalek R; Mechal H; Zahidi H; Mounaouir K; Arous S; Benouna MEG; Drighil A; Habbal R
J Med Case Rep; 2021 Feb; 15(1):76. PubMed ID: 33593422
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia Vera Presenting as ST-Segment Elevation Myocardial Infarction.
Hirsch E; Qunaj L; Latib A; Galen B
Am J Med; 2022 Aug; 135(8):964-965. PubMed ID: 35367440
[No Abstract] [Full Text] [Related]
11. Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients.
Krečak I; Holik H; Zekanović I; Morić Perić M; Marketin T; Coha B; Gverić-Krečak V; Vodanović M; Lucijanić M
Thromb Res; 2022 Jan; 209():47-50. PubMed ID: 34864474
[No Abstract] [Full Text] [Related]
12. [Acute myocardial infarction due to polycythemia vera].
Huart J; Visée C; Colassin A; Maréchal P; Hafraoui K; Davin L
Rev Med Liege; 2018 Jul; 73(7-8):397-401. PubMed ID: 30113781
[TBL] [Abstract][Full Text] [Related]
13. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
Williams DM; Kim AH; Rogers O; Spivak JL; Moliterno AR
Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
[TBL] [Abstract][Full Text] [Related]
15. [How I manage polycythemia].
Lombardo G; Hafraoui K; Beguin Y; Vertenoeil G
Rev Med Liege; 2024 Feb; 79(2):110-115. PubMed ID: 38356428
[TBL] [Abstract][Full Text] [Related]
16. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
17. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation.
Bernardi M; Ruggeri M; Albiero E; Madeo D; Rodeghiero F
Am J Hematol; 2009 Apr; 84(4):258-60. PubMed ID: 19229983
[No Abstract] [Full Text] [Related]
18. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
19. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
20. Neuropsychiatric Derangement by Polycythemia Vera: A Case Report of an Unexpected Disease Presentation and Review of the Literature.
De Lil H; van Beek M; Herbers A; van der Holst E; Keijsers K
Acta Haematol; 2021; 144(6):706-711. PubMed ID: 34247161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
